Neuronetics Inc (STIM)
1.83
+0.03
(+1.67%)
USD |
NASDAQ |
Dec 08, 16:00
1.77
-0.06
(-3.28%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 52.95M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -70.48% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.7448 |
| Price to Book Value | 1.396 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.9713 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 96.59% |
Profile
| Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options. |
| URL | https://www.neurostar.com |
| Investor Relations URL | http://ir.neuronetics.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Mar. 07, 2024 (est.) |
| Last Earnings Release | Nov. 07, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options. |
| URL | https://www.neurostar.com |
| Investor Relations URL | http://ir.neuronetics.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Mar. 07, 2024 (est.) |
| Last Earnings Release | Nov. 07, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |